127 related articles for article (PubMed ID: 1347075)
1. Steepness of the clinical dose-control curve and variation in the in vitro radiosensitivity of head and neck squamous cell carcinoma.
Bentzen SM
Int J Radiat Biol; 1992 Mar; 61(3):417-23. PubMed ID: 1347075
[TBL] [Abstract][Full Text] [Related]
2. Relationship between tumour cell in vitro radiosensitivity and clinical outcome after curative radiotherapy for squamous cell carcinoma of the head and neck.
Stausbøl-Grøn B; Overgaard J
Radiother Oncol; 1999 Jan; 50(1):47-55. PubMed ID: 10225557
[TBL] [Abstract][Full Text] [Related]
3. Oxygen distributions partly explain the radiation response of human squamous cell carcinomas.
Okunieff P; de Bie J; Dunphy EP; Terris DJ; Höckel M
Br J Cancer Suppl; 1996 Jul; 27():S185-90. PubMed ID: 8763877
[TBL] [Abstract][Full Text] [Related]
4. Does variation in the in vitro cellular radiosensitivity explain the shallow clinical dose-control curve for malignant melanoma?
Bentzen SM; Thames HD; Overgaard J
Int J Radiat Biol; 1990 Jan; 57(1):117-26. PubMed ID: 1967283
[TBL] [Abstract][Full Text] [Related]
5. The modelled benefits of individualizing radiotherapy patients' dose using cellular radiosensitivity assays with inherent variability.
Mackay RI; Hendry JH
Radiother Oncol; 1999 Jan; 50(1):67-75. PubMed ID: 10225559
[TBL] [Abstract][Full Text] [Related]
6. A realistic closed-form radiobiological model of clinical tumor-control data incorporating intertumor heterogeneity.
Roberts SA; Hendry JH
Int J Radiat Oncol Biol Phys; 1998 Jun; 41(3):689-99. PubMed ID: 9635721
[TBL] [Abstract][Full Text] [Related]
7. Impact of the tumour bed effect on microenvironment, radiobiological hypoxia and the outcome of fractionated radiotherapy of human FaDu squamous-cell carcinoma growing in the nude mouse.
Zips D; Eicheler W; Brüchner K; Jackisch T; Geyer P; Petersen C; van der Kogel AJ; Baumann M
Int J Radiat Biol; 2001 Dec; 77(12):1185-93. PubMed ID: 11747543
[TBL] [Abstract][Full Text] [Related]
8. Does heterogeneity of pimonidazole labelling correspond to the heterogeneity of radiation-response of FaDu human squamous cell carcinoma?
Yaromina A; Hölscher T; Eicheler W; Rosner A; Krause M; Hessel F; Petersen C; Thames HD; Baumann M; Zips D
Radiother Oncol; 2005 Aug; 76(2):206-12. PubMed ID: 16024121
[TBL] [Abstract][Full Text] [Related]
9. Predictive value of modelled tumour control probability based on individual measurements of in vitro radiosensitivity and potential doubling time.
Hedman M; Björk-Eriksson T; Brodin O; Toma-Dasu I
Br J Radiol; 2013 May; 86(1025):20130015. PubMed ID: 23479396
[TBL] [Abstract][Full Text] [Related]
10. Dose fractionation and regeneration in radiotherapy for cancer of the oral cavity and oropharynx: tumor dose-response and repopulation.
Maciejewski B; Withers HR; Taylor JM; Hliniak A
Int J Radiat Oncol Biol Phys; 1989 Mar; 16(3):831-43. PubMed ID: 2921175
[TBL] [Abstract][Full Text] [Related]
11. In vitro radiosensitivity of tumour cells and fibroblasts derived from head and neck carcinomas: mutual relationship and correlation with clinical data.
Stausbøl-Grøn B; Bentzen SM; Jørgensen KE; Nielsen OS; Bundgaard T; Overgaard J
Br J Cancer; 1999 Mar; 79(7-8):1074-84. PubMed ID: 10098739
[TBL] [Abstract][Full Text] [Related]
12. Acute and late toxicity, tumour control and intrinsic radiosensitivity of primary fibroblasts in vitro of patients with advanced head and neck cancer after concomitant boost radiochemotherapy.
Rudat V; Dietz A; Nollert J; Conradt C; Weber KJ; Flentje M; Wannenmacher M
Radiother Oncol; 1999 Dec; 53(3):233-45. PubMed ID: 10660204
[TBL] [Abstract][Full Text] [Related]
13. Pre-treatment number of clonogenic cells and their radiosensitivity are major determinants of local tumour control after fractionated irradiation.
Yaromina A; Krause M; Thames H; Rosner A; Krause M; Hessel F; Grenman R; Zips D; Baumann M
Radiother Oncol; 2007 Jun; 83(3):304-10. PubMed ID: 17517444
[TBL] [Abstract][Full Text] [Related]
14. Fractionation sensitivities and dose-control relations of head and neck carcinomas: analysis of the randomized hyperfractionation trials.
Stuschke M; Thames HD
Radiother Oncol; 1999 May; 51(2):113-21. PubMed ID: 10435801
[TBL] [Abstract][Full Text] [Related]
15. Radiosensitivity of dermal and tumor fibroblasts derived from the same patient.
Honkanen J; Rantanen V; Kulmala J; Grénman R; Klemi P; Pekkola K
J Cancer Res Clin Oncol; 1998; 124(8):415-20. PubMed ID: 9750017
[TBL] [Abstract][Full Text] [Related]
16. Optimum parameters in a model for tumour control probability, including interpatient heterogeneity: evaluation of the log-normal distribution.
Keall PJ; Webb S
Phys Med Biol; 2007 Jan; 52(1):291-302. PubMed ID: 17183142
[TBL] [Abstract][Full Text] [Related]
17. Comparison of cellular radiosensitivity between different localizations of head and neck squamous-cell carcinoma.
Pekkola-Heino K; Jaakkola M; Kulmala J; Grénman R
J Cancer Res Clin Oncol; 1995; 121(8):452-6. PubMed ID: 7642686
[TBL] [Abstract][Full Text] [Related]
18. Does skin fibroblast radiosensitivity predict squamous cancer cell radiosensitivity of the same individual?
Haikonen J; Rantanen V; Pekkola K; Kulmala J; Grénman R
Int J Cancer; 2003 Mar; 103(6):784-8. PubMed ID: 12516099
[TBL] [Abstract][Full Text] [Related]
19. Predicting the radiation control probability of heterogeneous tumour ensembles: data analysis and parameter estimation using a closed-form expression.
Fenwick JD
Phys Med Biol; 1998 Aug; 43(8):2159-78. PubMed ID: 9725596
[TBL] [Abstract][Full Text] [Related]
20. Time-dose-response relationships in postoperatively irradiated patients with head and neck squamous cell carcinomas.
Muriel VP; Tejada MR; de Dios Luna del Castillo J
Radiother Oncol; 2001 Aug; 60(2):137-45. PubMed ID: 11439208
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
